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Abstract
Purpose Perfusion CT (PCT) measurements of regional
cerebral blood flow (rCBF) have been proposed as a fast
and easy method for identifying angiogenically active
tumours. In this study, quantitative PCT rCBF measure-
ments in patients with brain tumours were compared to the
gold standard PET rCBF with 15O-labelled water (15O-
H2O).
Methods On the same day within a few hours, rCBF was
measured in ten adult patients with treatment-naïve primary
brain tumours, twice using 15O-H2O PET and once with
PCT performed over the central part of the tumour. Match-
ing rCBF values in tumour and contralateral healthy regions
of interest were compared.
Results PCT overestimated intratumoural blood flow in all
patients with volume-weighted mean rCBF values of 28.2±
18.8 ml min−1 100 ml−1 for PET and 78.9±41.8 ml min−1
100 ml−1 for PCT. There was a significant method by
tumour grade interaction with a significant tumour grade
rCBF difference for PCT of 32.9±15.8 ml min−1 100 ml−1
for low-grade (WHO I + II) and 81.5±15.4 ml min−1
100 ml−1 for high-grade (WHO III + IV) tumours, but not
for PET. The rCBF PCT and PET correlation was only
significant within tumours in two patients.
Conclusion Although intratumoural blood flow measured
by PCT may add valuable information on tumour grade,
the method cannot substitute quantitative measurements of
blood flow by PET and 15O-H2O PET in brain tumours.
Keywords PET . Brain perfusion . Brain tumour . Oxygen
radioisotopes . Perfusion CT
Introduction
The recent technical developments in fast multidetector CT
and commercial software solutions have enabled a fast,
relatively simple, practical and available approach to assess
essential parameters of vascular physiology, namely regional
cerebral blood flow (rCBF), regional cerebral blood volume
(rCBV) and the permeability-surface area product (PS)—a
measure of blood-brain barrier permeability [1]. This tech-
nique, known as perfusion CT (PCT), has primarily found
routine clinical use in the management of acute ischaemic
stroke and is considered a valid alternative to perfusion-
weighted MRI (PWI)[1, 2]. In oncology there is a growing
interest in methods for evaluation of tumour-associated neo-
vasculature. This process, known as angiogenesis, is induced
early during the multistage development of invasive cancers
and has long been recognized as one of the important integral
hallmarks of cancer [3]. PCT has clinical value in neuro-
oncology and can contribute to the preoperative grading of
primary brain tumours [4]. An effective option would be to
add PCT to molecular imaging studies already being
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performed in the clinical workup of brain tumour patients
using hybrid PET/CT scanning systems. If equipped with
state-of-the-art multislice CT scanners with 40–128 detector
rows that, using constant periodic bidirectional table move-
ments, can cover 96 mm of the brain in the z-axis [4], it
would extend the utility of CT to provide further clinical
information—not just low-dose CT for attenuation correction,
thus mimicking the multiparametric approach that is now the
standard strategy using MRI. PCT might thereby give a fin-
gerprint of the tumour microenvironment combining vascular
physiological measures with radioisotope images of tissue
hypoxia [5], amino acid transport, tumour proliferation [6]
or glucose metabolism [7] in a single session. This opportu-
nity for studying the metabolism/perfusion relationship with
PET/PCT had been recognized early on [1], but is rarely
utilized [8, 9].
The precondition, however, is that PCT measurements
obtained in a tumour using standard methods are robust and
reliable and relate genuinely quantitative physiological
parameters. In a previous independent study, using healthy
subjects, we found this not to be the case. There was a
significant overestimation of rCBF by PCT in grey matter
of 47 % on average, validated against a recognized gold
standard, PET with 15O-labelled water [10].
The aim of this study was to compare PCT to the gold
standard 15O-H2O PET for brain perfusion, both calculated
with a deconvolution approach in a prospective study of the
two techniques. These assessments were performed directly
preoperatively in patients with primary brain tumours, on
the same day, within a few hours.
Materials and methods
Patients
Ten adult patients (four women and six men) with a median
age of 53 years (range 24–63 years) were recruited prospec-
tively and scanned from October 2008 to December 2010.
The inclusion criteria were patients with initial untreated
presentations of suspected primary supratentorial brain
tumours based on the MRI findings. The exclusion criteria
were systemic malignancies, reduced renal function, preg-
nancy, biguanide-treated diabetes and known allergy to io-
dinated contrast media. The plasma creatinine levels of all
patients were measured within 2 weeks before the scan and
were all within the normal range. The protocol was ap-
proved by the Committees on Biomedical Research Ethics
for the Capital Region of Denmark (protocol number H-A-
2008-055). All patients gave oral and written informed
consent according to the Helsinki II Declaration. Nine of
the patients had intra-axial tumours and one had an extra-
axial tumour (meningioma). All patients with high-grade
glioma (WHO III and IV) with the exception of one (n04)
were treated with corticosteroids before and during PET and
CT scanning. Antiepileptic drugs were administered to six
patients. Tumour tissue was biopsied a median of 12 days
(range 3–453 days) after PET and CT scanning periopera-
tively and histologically verified and graded according to
the WHO criteria by an experienced neuropathologist
(H.B.). The patients and their tumours are characterized in
Table 1.
Imaging
All patients had pre- and post-contrast MRI scans as part of
the routine preoperative workup including standard T1-
weighted imaging with and without gadolinium-based con-
trast, T2-weighted imaging and fluid-attenuated inversion
recovery (FLAIR). This was performed a median of 19 days
before rCBF PET and CT scanning (range 8–110 days).
PET protocol
Scanner A dedicated brain HRRT (High Resolution Re-
search Tomograph) PET scanner (CTI/Siemens, Knoxville,
TN, USA) was used for all 15O-H2O PET scans. This scan-
ner has an axial field of view of 25 cm and a near isotropic
resolution of 2 mm.
PET tracer For the scan, 800 MBq 15O-H2O was produced
online and injected intravenously into an antecubital vein
via an Automatic Water Injection System (AWIS 1997,
Scansys by Peter Larsen, Denmark). AWIS delivered a 16-
ml bolus over 10 s with both pre-flush and after-flush of an
inert saline solution [11].
Nine patients received two tracer injections, and one
patient had only one tracer injection because of clotting in
the arterial catheter after the first scan. A short indwelling
catheter was placed in the non-dominant radial artery under
local anaesthesia for blood sampling.
Image acquisition During scanning, the patient’s head res-
ted in a foam-cushioned headrest, and a head strap was used
to minimize head movement. Initially a 6-min transmission
scan with a rotating 137Cs single photon point source was
performed for attenuation correction. The 7-min emission
scans were acquired in 3D list mode and initiated immedi-
ately before tracer injection. The interscan interval was at
least 10 min to allow for isotope decay.
For kinetic modelling arterial blood was sampled contin-
uously during the scans using an automatic blood sampling
system (Allogg ABSS, Mariefred, Sweden) set to draw
arterial blood at a constant speed of 8 ml/min with activity
measures every 0.5 s. The inner diameter of the tube
connected to the arterial catheter was 1.0 mm. The detectors
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in the ABSS and the PET scanner were cross-calibrated
against an independent dose calibrator so that all data could
be reported in radioactivity concentration (Bq/ml). Immedi-
ately after the scan, 2 ml arterial blood was drawn for blood
gas analysis to evaluate the physiological respiratory state of
the patient. The samples were analysed for arterial partial
pressure of oxygen and carbon dioxide (PaO2, PaCO2),
saturation level of oxygen (sO2) and haemoglobin concen-
tration (ctHb) (ABL 700 Series, Radiometer Medical,
Copenhagen, Denmark).
Image reconstruction Dynamic images were reconstructed
using a 3D ordered subset expectation maximization algo-
rithm with correction for the measured point spread function
(3D-OSEM-PSF) into 40 frames per scan of 1×30, 18×5,
9×10, 10×15 and 2×30 s durations. Each frame consisted
of 207 image planes in a 256×256 matrix with an isotropic
voxel size of 1.22×1.22×1.22 mm3. The first 30-s frame
was designed to accommodate the tracer delay from injec-
tion to brain tissue. All images were corrected for randoms,
scatter, attenuation, decay and dead time and filtered with a
3D Gaussian 5-mm filter.
PET CBF calculation Using a commercially available soft-
ware package, PMOD 3.0 (PMOD Technologies, Zürich,
Switzerland), the dynamic images of the first 210 s follow-
ing arrival of activity to the brain and the delay and
dispersion-corrected arterial input function [12] were fitted
by a standard one-tissue compartment model (“Alpert’s one-
tissue compartment model”) [13, 14] according to Eq. 1.
CtðtÞ ¼ fCaðtÞ  e f VT=ð Þt ð1Þ
where C(t) denotes tissue activity concentration (Bq/ml), Ca
(t) the measured arterial input function (Bq/ml), f is rCBF
(ml min−1 100 ml) and VT (ml/g) is the fitted volume of
distribution. ⊗ represents the convolution operation. This
generated parametric images of rCBF.
Radiation dose The dose equivalent following PET trans-
mission and emission scans was in total 1.6 mSv,
0.1 mSv for the transmission scan and 0.74 mSv for
each emission scan.
CT protocol
Scanner Biograph 40 TruePoint PET/CT scanner (Siemens,
Knoxville, TN, USA) with a 40 detector row CT was used.
Contrast media A preheated iso-osmolar iodine contrast
medium OptiRay 350 (Ioversol 350 mg/ml, Tyco Health-
care, Neustadt/Donau, Germany) was injected intravenously
by a power injector (OptiVantage DH Injection System,
Liebel-Flarsheim, Cincinnati, OH, USA) as a short bolus
of 40 ml (8 ml/s) through a catheter in the antecubital vein
followed by 20 ml saline solution.
Image acquisition The PET scanning was, for practical rea-
sons, performed in all patients before CT on the same day
and within 1–4 h. A lateral scout scan at the angle of the
meato-orbital plane was performed followed by a non-
enhanced low-dose CT (120 kVp, 40 mAs). The selection
of four contiguous transaxial slices with a coverage of
28 mm through the centre of the tumour was guided with
reference to the corresponding contrast-enhancing T1-
weighted MRI or T2-weighted MRI in non-enhancing
tumours. This was done either visually or by direct MRI to
Table 1 Patient characteristics
Patient Age Sex Tumour type WHO grade Side Lobe Measure Prednisone AED CE Appearance
1 32 M Astrocytoma II R T 5×9×3 − − − Solid
2 64 M Glioblastoma multiforme IV L T 4×5×4 + + + Cystic
3 55 F Astrocytoma II R F 5×6×5 + + + Solid
4 53 F Neuroepithelial tumour II R P 3×3×3 − + − Solid
5 63 M Glioblastoma multiforme IV L T 5×4×4 + − + Cystic/solid
6 46 F Meningioma I L F 4×5×5 + + + Cystic/solid
7 56 M Glioblastoma multiforme IV R F 5×5×3 + − + Cystic/solid
8 30 M Anaplastic oligodendroglioma III R P 2×2×2 − + + Cystic/solid
9 24 F Astrocytoma II L F 4×5×4 − + + Cystic/solid
10 55 M Glioblastoma multiforme IV R F 5×5×6 + − + Cystic/solid
Tumour type and tumour grade listed according to the WHO classification. Measures are in centimetres, side-to-side, anteroposterior, craniocaudal
to the nearest centimetre. High-grade tumours are marked in bold
AED antiepileptic drugs, CE contrast enhancement in the tumour with T1-weighted MRI scan, F frontal, T temporal, P parietal
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low-dose CT coregistration on a separate workstation next to
the CT acquisition computer. The orbital fossa was avoided
in order to reduce irradiation to the lens of the eye. The
contrast medium was injected 4 s before initiation of the
dynamic scan. The dynamic scan consisted of 160 images:
one image/s for 40 s over four slices 7.2 mm thick at 80
kVp, 200 mAs for patients 1-6 and 80 kVp, 120 mAs for
patients 7-10. The arterial cannula from the PET scan was
kept in place and used to draw arterial blood for blood gas
analysis immediately after the scan.
Image reconstruction and rCBF calculation Each slice was
reconstructed into a 512×512 image matrix using an H30s
medium smooth kernel. Voxel dimensions were non-
isotropic 0.44×0.44×7.2 mm3. The rCBF was calculated
in a semi-automated manner using commercial software,
Syngo Neuro Perfusion CT 2006A (Siemens). After seg-
mentation and removal of extra-cerebral tissue, a circular
reference region of interest (ROI) was defined automatically
in the occipital part of the superior sagittal sinus. Maximum
intensity projections (MIP-CT) were reconstructed to en-
hance areas of high radiodensity that are useful for identi-
fying vascular structures. The larger vessels were removed
by thresholding the MIP-CT image by 15 %. The arterial
input function was derived from the time-attenuation curve
from ROIs comprising either anterior cerebral arteries in
cross section or medial cerebral arteries, or both, and the
rCBF was calculated using a deconvolution approach [15].
Radiation dose The effective dose equivalent was 2.9 mSv
for the CT protocol at 120 mAs and 3.8 mSv at 200 mAs.
Data analysis
Image coregistration and regions of interest Using PMOD,
rCBF PET, rCBF CT and MRI images were coregistered to
the low-dose CT scan of the head to a final voxel size of
0.5×0.5×1.5 mm3. This was done to ensure that all ROIs
referred to and included an identical tissue composition
throughout all techniques. On the MRI images, ten non-
overlapping and independent circular ROIs with a diameter
of 7.2 mm and a sample volume of 61 mm3 were drawn, an
irregular freehand ROI in normal appearing contralateral grey
matter and an ellipsoid in normal appearing contralateral
white matter. The tumour ROIs were, as far as possible, placed
outside highly vascular regions. This, however, was difficult,
particularly in the high-grade glioma. Vascular voxels within
an ROI with an rCBV larger than 15 ml/100 g were excluded
from analysis by a masking technique. In patient 5, suffering
from a cystic glioblastoma multiforme with a thin highly
vascularized tissue rim, only six ROIs could be confidently
placed. Finally, the ROIs were projected onto identical areas
of the masked parametric rCBF PET and rCBF CT images for
quantification (Figs. 1 and 2). The tissue volume in the tumour
ROIs ranged from 30 to 63 mm3 (mean 54 mm3), in white
matter from 123 to 357 mm3 (mean 228 mm3) and in grey
matter from 321 to 938 mm3 (mean 572 mm3). We then
calculated the volume-weighted average tumour values based
on the ROIs.
Statistical methods
The statistical analysis was conducted using MATLAB
(MathWorks Inc., Natick, MA, USA). Paired t tests with a
two-tailed significance level of α00.05 were used to test for
differences in the measures of blood gas data. A similar
method was used for the analyses between rCBF CT and
the average of two rCBF PET scans within each patient for
every tumour, and between patients for the volume-
weighted tumour rCBF, and for the white and grey matter
rCBF. In the clinical use of PCT and MRI it is recognized
that the global variation may significantly influence the
regional variation. We therefore normalized the tumour
and grey matter rCBF to the normal appearing white matter
rCBF and repeated the statistical analysis.
The Bland-Altman test was used to assess the agreement
between corresponding tumour measurements. The mean
difference, standard deviations and the 95 % limits of agree-
ment were calculated and plotted. For tumours the intra-
patient and between-patient correlation of the two methods
was calculated using linear regression analyses as well as
the coefficient of determination (r2) between methods.
For both absolute and white matter normalized values we
used a two-way analysis of variance (ANOVA) for model-
ling the interaction effect and the main effects of two factors,
namely imaging technique (PET or PCT) and tumour grade
[low (WHO grade I and II) or high (WHO grade III and
IV)]. Also, we performed unpaired t tests with a two-tailed
significance level of α00.05 to test for differences between
high- and low-grade tumours for both absolute and white
matter normalized rCBF values, for PET and PCT sep-
arately. These analyses comprised only the glioma with
exclusion of one outlier, patient 9 with grade II astro-
cytoma (Table 1) and unusually high tumour tissue
perfusion on PET and PCT.
Results
Blood gas analyses
Eight patients were included in the blood gas analysis
(Table 2). For the two excluded patients, the arterial cannula
malfunctioned before arterial blood samples were drawn.
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The ctHb and sO2 did not change significantly between the
PET and PCT studies. The PaCO2, however, dropped sig-
nificantly by 0.5 kPa, or 4 mmHg, and the PaO2 increased
by 1.9 kPa or 14 mmHg from PET scan to PCT scan. This
indicates hyperventilation during performance of PCT.
Regional cerebral blood flow measures
The analysed mean volume of the tumours was 0.52±
0.11 ml (data not shown). In tumours, volume-weighted
mean rCBF values were 28.2±18.8 (range 12.1–73.2)
ml min−1 100 ml−1 for PET and 78.9±41.8 (range 14.7–
142.2) ml min−1 100 ml−1 for PCT (Table 3). In all but one
patient, PET and PCT values differed significantly. The r2
ranged from 0.02 to 0.91, mean 0.22, and three patients had
significant intratumoural correlation between PET and PCT
values. Using PET, mean tumour blood flow was not sig-
nificantly different between low (I–II) or high (III–IV)
WHO graded gliomas measured at 18.4±8.3 and 21.5±
7.0 ml min−1 100 ml−1, respectively (Table 4). In PCT,
however, there was a significant tumour grade difference
(p<0.01) in perfusion with values of 32.9±15.8 and 81.5±
15.4 ml min−1 100 ml−1 for low and high grade, respective-
ly. Both grey and white matter values were extracted from
the patients’ scans (Table 3). The mean grey matter value
was 34.9±8.8 ml min−1 100 ml−1 in PET and 74.6±
13.7 ml min−1 100 ml−1 in PCT, and the mean white matter
value was 15.9±4.8 ml min−1 100 ml−1 in PET and 29.7±
3.9 ml min−1 100 ml−1 in PCT. These differences were
significant.
Mean ratios of tumour rCBF over white matter rCBF
were 1.7±0.8 and 2.7±1.5 for PET and PCT, respectively,
including all patients. This quite large difference in normal-
ized rCBF values between modalities was significant for six
of ten patients. The mean ratio of grey over white matter was
2.2±0.4 for PET and 2.5±0.4 for PCT. This difference
between modalities was also significant. When tumour per-
fusion was normalized to white matter there was only a
significant difference between tumour grade for PCT
(p<0.005; low grade 1.1±0.4; high grade 2.7±0.5), but
not for PET (low grade 1.2±0.4; high grade 1.6±0.5;
Table 4).
The ANOVA of absolute and white matter normalized
tumour perfusion both revealed a significant main effect of
technique (PCT>PET), a significant main effect of grade
(high grade>low grade) and a significant interaction effect
(technique × grade) (Fig. 3). The grade and the interaction
effects are likely to be driven by the high rCBF in high-grade
tumours measured with PCT, as the difference between grades
only were significant using PCT, not using PET.
The within-patient correlation of rCBF between modali-
ties was significant for three patients (Table 3). The
Fig. 1 Patients with
coregistered transaxial slices of
post-contrast preoperative T1-
weighted MRI, rCBF PET and
PCT scans (ml min−1 100 ml−1)
documenting the locations of
ROIs. Highly vascular areas are
eliminated in PCT. Patient 1
suffered from a heterogeneous,
non-enhancing astrocytoma
(grade II) with central hypoper-
fused and posterior hyperper-
fused areas. Patient 2 had a
cystic ring-enhancing moder-
ately perfused glioblastoma
multiforme (grade IV). Patient 3
had an enhancing uniformly
hypoperfused astrocytoma
(grade II). Note the different
scaling of rCBF PET and rCBF
CT images. The top row shows
T1-weighted MR images with
gadolinium contrast
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between-subject whole tumour rCBF correlation was signif-
icant when using absolute values (r200.5, slope 1.6; inter-
cept 32.6 ml min−1 100 ml−1; Fig. 4), and even better when
values normalized to the white matter were used (r200.7;
slope 1.6; intercept 1.0). A Bland-Altman plot over each
individual ROI shows bias for PCT rCBF values, which
increases with increasing tumour rCBF values (Fig. 5), and
the bias is similar for the three tumour types mentioned in
this study.
Discussion
In this study, our objective was to test the validity of the
preoperative quantitative measurements of rCBF in ten
patients with brain tumours using PCT, a novel and prom-
ising technique, against the gold standard 15O-H2O PET
[16] (Table 1). We found that PCT overestimated gliomatous
tumour rCBF values compared to 15O-H2O PET by 22–
672 %.
First, we examined both absolute quantified rCBF values
and rCBF values normalized to healthy appearing white
matter in the hemisphere contralateral to the malignancy
for both methods, PCT and PET. Normalization is used as
a standard method in the evaluation of tumours in MRI [17,
18] and PCT [19] to increase the robustness of the regional
physiological measures (rCBV, rCBF) by removing global
variation influenced by particular aspects of the technique,
e.g. the quality and corrections of the arterial input function
[20, 21], variations in cardiac output [22] or variations in
ctHb or blood gas levels (see later).
Other research groups have quantified blood flow of
different tumour types of the brain with 15O-H2O PET
[23]. Meningiomas were listed with a mean CBF of 57±
22 ml min−1 100 g−1, which corresponds well to our patient
with grade I meningioma (patient 6), who had a tumour
CBF of 45.9 ml min−1 100 ml−1. For the neuroepithelial
tumours, results are reported with more variation [24–26],
and rCBF varies greatly between tumours. In our study, data
confirm that this is even true within the tumours, regardless
of grade [27]. This is reflected in the sometimes large stan-
dard deviation of the mean CBF measured by PET perfusion
(Table 3), ranging from 11 to 58 %. Also, contralateral grey
matter perfusion values were generally lower than mean grey
matter perfusion values measured on healthy subjects in PET,
34.9±8.8 and 48.7±5.0 ml min−1 100 ml−1, respectively [10],
which confirms data from Mineura et al. that grey matter
perfusion can be suppressed in patients with brain tumours,
even on the contralateral, healthy side [25].
In a study of the clinical applicability of CBF estimated
with PCT in patients with gliomas, the normalized values of
CBV correlated with tumour grade [19]. Their normalized
CBF values with PCT (high grade CBF 2.7±0.5, low grade
1.1±0.4) compare well with our values (Table 4).
Evaluating the relative distribution between rCBF values,
there was generally speaking a good match between both
PET and PCT images in patients with low-grade glioma
(Fig. 1) as well as between PET and PCT rCBF values.
For high-grade glioma, however, there was a mismatch with
rCBF values in the tumour clearly above the values in grey
matter in PCT and below grey matter in PET (Table 4).
Furthermore, one patient with glioblastoma multiforme
had a hyperperfused area on both repeated rCBF PET scans
anterior to the tumour situated in normally appearing cortex
Table 2 Blood gas measurements (n08)
rCBF PET rCBF CT p value
PaCO2 (kPa) 5.6±0.59 5.1±0.57 < 0.05
PaO2 (kPa) 11.8±1.47 13.7±1.83 < 0.05
ctHb (mmol/l) 8.5±1.41 7.5±1.72 NS
sO2 (%) 0.96±0.01 0.97±0.05 NS
PaCO2 arterial partial pressure of carbon dioxide, PaO2 arterial partial
pressure of oxygen, ctHb haemoglobin concentration, sO2 oxygen
saturation, all listed as mean ± SD
Fig. 2 Coregistered transaxial slices of post-contrast preoperative T1-
weighted MRI and FLAIR sequences (top row) performed 15 days
prior to rCBF PET and rCBF CT scans (bottom row) in patient 7,
suffering from glioblastoma multiforme (grade IV). The tumour has a
hypoperfused cystic necrotic centre and heterogeneous hypo- and
hyperperfusion in the contrast-enhancing wall. PET shows a hyper-
perfused area anterior to the tumour (arrow) that cannot be identified
on rCBF CT performed within 2 h. This is likely to represent a
transient non-convulsive epileptic seizure. rCBF is measured in
ml min−1 100 ml−1
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above the tumour oedema. This was not visualized in the
subsequent PCT performed a few hours later and thus con-
stitutes an obvious mismatch (patient 7, Fig. 2). We do not,
however, believe this to be angiogenic activity in malignant
tissue, as it would be unlikely that this relatively large area
would not be apparent on MRI. More likely it is hyper-
perfusion, secondary to synchronous neuronal activity
linked to a focal non-convulsive epileptic seizure that sub-
sequently resolved prior to PCT. There were no obvious
clinical signs of a seizure, but it is a well-known pitfall in
the evaluation of 18F-fluorodeoxyglucose (FDG) PET scans
of brain tumours, and it can be expected to pose a similar
problem when identifying angiogenically active tumour tis-
sue with PCT or MRI.
There is evidence to suggest that high angiogenic activity
in itself, measured by rCBF with MRI, has predictive infor-
mation of tumour progression or death independent from
tumour grade [18]. The patient in our series with the highest
tumour perfusion on both PET and PCT had in fact a low-
grade astrocytoma (patient 9, Table 1). In another patient
with a low-grade glioma (patient 1, Fig. 1) we found a
heterogeneous distribution of rCBF values including hyper-
perfused tumour tissue. Thus, high angiogenic activity in
itself is not a trait reserved only for high-grade tumours, and
these patients would be false positives if grading was based
on rCBF alone. Similar findings have been presented previ-
ously [18–28]. Interestingly, we found a significant method-
dependent difference regarding the ability to grade tumours
based on rCBF. Thus, there was a significant difference
between tumour grade measuring rCBF with PCT, but not
with PET. These results match the data obtained using
steady-state susceptibility contrast-enhanced MRI (ssCE-
MRI). With this MRI sequence it is possible to preferentially
sensitize the rCBV measurements toward either all tumour
vessel components or selectively the microvascular seg-
ments (<30 μm) using either gradient-echo echo-planar
imaging (GE-EPI) or spin-echo echo-planar imaging (SE-
EPI), respectively [29]. No significant difference was found
Table 3 rCBF measurements from PET and CT scanning
Patient Tumour Grey matter White matter Tumour normalized Grey matter normalized
PET CT r2 PET CT PET CT PET CT PET CT
1 27.8±16.1 43.4±32.8* 0.91** 32.9 70.9 16.5 34.1 1.7±1.0 1.3±1.0* 2.0 2.1
2 29.2±5.2 71.0±9.9* 0.06 49.7 64.7 20.7 24.5 1.4±0.3 2.9±0.4* 2.4 2.6
3 12.1±1.3 14.7±4.8 0.08 45.9 58.5 21.8 26.4 0.6±0.1 0.6±0.2 2.1 2.2
4 15.4±1.7 40.5±10.1* 0.05 27.9 81.5 12.2 29.5 1.3±0.1 1.4±0.3 2.3 2.8
5 12.4±4.8 96.2±22.0* 0.14 20.9 81.7 11.3 36.6 1.1±0.4 2.6±0.6* 1.8 2.2
6 45.9±20.1 142.2±53.8* 0.55** 35.1 62.7 20.7 29.9 2.2±1.0 4.8±1.8* 1.7 2.1
7 27.5±12.3 82.6±18.4* 0.02 32.5 77.9 11.7 26.9 2.3±1.1 3.1±0.7 2.8 2.9
8 17.1±2.8 61.4±19.8* 0.03 32.8 101.2 11.4 32.0 1.5±0.2 1.9±0.6 2.9 3.2
9 73.2±19.3 141.0±32.2* 0.08 42.7 60.2 21.6 25.7 3.4±0.9 5.5±1.3* 2.0 2.3
10 20.9±6.8 96.3±36.8* 0.31** 28.9 86.7 11.4 31.4 1.8±0.6 3.1±1.2* 2.5 2.8
Mean ± SD 28.2±18.8 78.9±41.8*** 0.22 34.9±8.8 74.6±13.7*** 15.9±4.8 29.7±3.9*** 1.7±0.8 2.7±1.5*** 2.2±0.4 2.5±0.4***
Tumour, grey matter and white matter ROIs, and tumour ROIs and grey matter ROIs normalized with white matter, listed as mean ± SD. Volume-
weighted rCBF is given in ml min−1 100 ml−1 . High-grade tumours are marked in bold
*Significant difference between modalities in the individual patient, p <0.05
**Significant correlation between modalities in the individual patient, p <0.05
***Significant difference between modalities in all patients, p <0.05
Table 4 rCBF measurements from PET and CT scanning (n08)
Tumour Tumour normalized
PET CT r2 PET CT
Total low-grade tumours 18.4±8.3 32.9±15.8 0.35±0.5 1.2±0.4 1.1±0.4
Total high-grade tumours 21.5±7.0 81.5±15.4 0.11±0.1 1.6±0.5 2.7±0.5
Tumour tissue perfusion in absolute measures and normalized to white matter, stratified according to WHO classification (Table 1), and listed as
mean±SD. Low grade: I-II (patients 1, 3, 4), high grade: III-IV (patients 2, 5, 7, 8, 10). Patient 6 excluded because of tumour type (meningioma).
Patient 9 excluded as an outlier
Blood flow is given in ml min−1 100 ml−1 . Ratios are volume weighted
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between high- and low-grade gliomas using SE-EPI, while
this was the case for GE-EPI [29–31]. It has been suggested
that the sizes of vessels within a tumour vary with the
aggressiveness and angiogenic activity of the tumour [32].
Thus, rCBF PET is primarily linked to the capillary level for
which rCBV SE-EPI would also be a surrogate MRI param-
eter. So performing measurements of the capillary function
does not appear as efficient in glioma grading, but these are
the parameters most likely to portray the tumour microen-
vironment, not least with respect to the exchange of solutes,
nutrients and chemotherapeutics.
On the other hand, PCT and GE-EPI that embrace all,
even nonfunctional, vascular segments might add value in
tumour grading [4–31] and offer a parameter to monitor the
effects of anti-angiogenic therapies [33, 34], but cannot be
used to examine the functional level of the tumour. These
hypotheses, however, need to be validated by a direct com-
parison between techniques.
As an integrated part of the validation between PCT and
PET, various error sources need to be considered. PET and
PCT were performed within 1–4 h on the same day and
always with PET performed before PCT for practical rea-
sons. We do not have to consider a day-to-day measurement
variance pertaining to variations in e.g. antiepileptic or
prednisone drug concentration. However, an order effect
cannot be excluded. The arterial blood gas analysis (Table 2)
showed a relatively hypocapnic status with a decrease of
4 mmHg in PCT compared to PET suggesting slight spon-
taneous hyperventilation, which can probably be ascribed to
an emotional response [35] in reaction to procedures relating






















Fig. 3 Comparison of rCBF PET and PCT by glioma grade. The
perfusion measuring technique interacts significantly with tumour
grade. rCBF for tumour grade is only significantly different when
measured with PCT. o: low-grade glioma, x: high-grade glioma, n08






















) y = 1.6 *x + 32.6




Fig. 4 The within-patient cor-
relation of PET and PCT meas-
urements. o: low-grade glioma,
x: high-grade glioma, ▽ : me-
ningioma, n010
1698 Eur J Nucl Med Mol Imaging (2012) 39:1691–1701
injection). Thus, the technique might have been a more
profound factor than scan order. Indeed, there is evidence
that PCT systematically affects the respiratory pattern: In a
previous independent study in healthy subjects we found
signs of significant hypocapnia during PCT [10]. The vaso-
reactivity in PCT has not been investigated systematically in
humans, but in PET a decrease in PaCO2 of 4 mmHg would
lower the rCBF in grey matter in the order of 8 % [36] and
an effect of the similar order in white matter [37]. In animal
models using implanted carcinoma cells, the tumour tissue
perfusion using PCT does respond to changes in PaCO2
level [38], albeit influenced by the anaesthesia used [38].
Furthermore, there are indications from MRI studies of
implanted gliomas in the rat brain that cerebral blood vessels
derived from tumour angiogenesis do retain reactivity to
CO2, however, with an augmented response to hypocapnia
compared to normal grey matter [39]. Whether these find-
ings can be transferred to de novo gliomas in humans is not
known. A similar physiology would lead not only to a
decrease in tumour tissue perfusion, but also a decrease in
the perfusion ratio of tumour to grey or white matter.
An important factor to explain the quantitative and qual-
itative difference between PCT and 15O-H2O PET adheres to
the fundamental differences between a CT non-diffusible
intravascular iodinated medium and a PET freely diffusible
tissue tracer. “Perfusion” refers to blood flow per unit func-
tional tissue mass. This would correspond to the attenuation
signal that in PCT derives from capillaries. However, be-
cause of the inherent limitations of resolution the capillary
signal cannot be discriminated from flow in larger vascular
structures up- or downstream from the capillary level. These
structures are not functional to the tumour tissue, in the
sense that there is no exchange of nutrients, medication or
tumour-derived humoral factors etc. across the vessel walls,
and their presence in the imaging field will increase perfu-
sion measurements erroneously. Adding to the difficulties is
the known chaotic and bizarre architecture of blood vessels
produced within tumours by chronically activated angiogen-
esis and an unbalanced mix of proangiogenic signals. Tu-
mour neovasculature is characterized by precocious
capillary sprouting, convoluted and excessive vessel branch-
ing, distorted and enlarged vessels, erratic blood flow,
micro-haemorrhaging, leakiness and arteriovenous shunts
[40]. Thus, even flow at the capillary level needs not be
functional. The freely diffusible PET tissue tracer, however,
does also have its limitations pertaining to the heteroge-
neous tumour tissue composition itself [41]. In fact the term
“multiforme” in glioblastoma multiforme refers exactly to
its heterogeneous macroscopic morphological presentation,
with areas that are either cystic, white and firm, yellow and
necrotic or red and haemorrhagic. There will indisputably be
cystic and necrotic tumour compartments that will not be
available for free exchange with 15O-labelled water. So
although the rCBF PCT and the PET ROIs are identical
and thus influenced equally by the tumour tissue heteroge-
neity, a purely intravascular tracer will overestimate perfu-
sion because of nonfunctional vascular structures, while a
freely diffusible tissue tracer will underestimate perfusion
because nonfunctioning tissue such as cysts are interpreted
as tumour tissue.
In conclusion, our study on gliomatous tumour rCBF
determined by PCT compared to the gold standard 15O-
H2O PET showed that PCT could not be used for absolute
measurements of tumour blood flow.


































Fig. 5 Bland-Altman plot. The
middle line indicates the mean
difference. The outer lines
indicate 95 % limits of
agreement. The differences
between rCBF PET and PCT
increase with increasing rCBF
values. o: low-grade glioma, x:
high-grade glioma, ▽ : menin-
gioma, n010
Eur J Nucl Med Mol Imaging (2012) 39:1691–1701 1699
Conflicts of interest None.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Miles KA. Brain perfusion: computed tomography applications.
Neuroradiology 2004;46 Suppl 2:s194–200.
2. Konstas AA, Goldmakher GV, Lee TY, Lev MH. Theoretic basis
and technical implementations of CT perfusion in acute ischemic
stroke, part 1: theoretic basis. AJNR Am J Neuroradiol
2009;30:662–8.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next genera-
tion. Cell 2011;144:646–74.
4. Xyda A, Haberland U, Klotz E, Bock HC, Jung K, Knauth M,
Schramm R, Psychogios MN, Erb G, Schramm P. Brain volume
perfusion CT performed with 128-detector row CT system in
patients with cerebral gliomas: a feasibility study. Eur Radiol
2011;21:1811–9.
5. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. As-
sessment of hypoxia and perfusion in human brain tumors using
PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med
2004;45:1851–9.
6. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J,
Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predict-
ing treatment response of malignant gliomas to bevacizumab and
irinotecan by imaging proliferation with [18F] fluorothymidine
positron emission tomography: a pilot study. J Clin Oncol
2007;25:4714–21.
7. Chen W. Clinical applications of PET in brain tumors. J Nucl Med
2007;48:1468–81.
8. Bisdas S, Spicer K, Rumboldt Z. Whole-tumor perfusion CT
parameters and glucose metabolism measurements in head and
neck squamous cell carcinomas: a pilot study using combined
positron-emission tomography/CT imaging. AJNR Am J Neuro-
radiol 2008;29:1376–81.
9. Groves AM, Wishart GC, Shastry M, Moyle P, Iddles S, Britton P,
Gaskarth M, Warren RM, Ell PJ, Miles KA. Metabolic-flow rela-
tionships in primary breast cancer: feasibility of combined PET/
dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging
2009;36:416–21.
10. Grüner J, Paamand R, Højgaard L, Law I. Brain perfusion CT
compared with15O-H2O-PET in healthy subjects. EJNMMI Res
2011;1:28.
11. Iida H, Law I, Pakkenberg B, Krarup-Hansen A, Eberl S, Holm S,
et al. Quantitation of regional cerebral blood flow corrected for
partial volume effect using O-15 water and PET: I. Theory, error
analysis, and stereologic comparison. J Cereb Blood Flow Metab
2000;20:1237–51.
12. Meyer E. Simultaneous correction for tracer arrival delay and
dispersion in CBF measurements by the H215O autoradiographic
method and dynamic PET. J Nucl Med 1989;30:1069–78.
13. Alpert NM, Eriksson L, Chang JY, Bergstrom M, Litton JE,
Correia JA, Bohm C, Ackerman RH, Taveras JM. Strategy for
the measurement of regional cerebral blood flow using short-lived
tracers and emission tomography. J Cereb Blood Flow Metab
1984;4:28–34.
14. Treyer V, Jobin M, Burger C, Teneggi V, Buck A. Quantitative
cerebral H2(15)O perfusion PETwithout arterial blood sampling, a
method based on washout rate. Eur J Nucl Med Mol Imaging
2003;30:572–80.
15. Kudo K, Sasaki M, Yamada K, Momoshima S, Utsunomiya H,
Shirato H, Ogasawara K. Differences in CT perfusion maps gen-
erated by different commercial software: quantitative analysis by
using identical source data of acute stroke patients. Radiology
2010;254:200–9.
16. Hoeffner EG. Cerebral perfusion imaging. J Neuroophthalmol
2005;25:313–20.
17. Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I,
Kira T, et al. Posttherapeutic intraaxial brain tumor: the value of
perfusion-sensitive contrast-enhanced MR imaging for differenti-
ating tumor recurrence from nonneoplastic contrast-enhancing tis-
sue. AJNR Am J Neuroradiol 2000;21:901–9.
18. Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML,
Miller DC, Golfinos JG, Zagzag D, Johnson G. Gliomas: predict-
ing time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-
enhanced perfusion MR imaging. Radiology 2008;247:490–8.
19. Ellika SK, Jain R, Patel SC, Scarpace L, Schultz LR, Rock JP, et al.
Role of perfusion CT in glioma grading and comparison with
conventional MR imaging features. AJNR Am J Neuroradiol
2007;28:1981–7.
20. Kamath A, Smith WS, Powers WJ, Cianfoni A, Chien JD, Videen
T, Lawton MT, Finley B, Dillon WP, Wintermark M. Perfusion CT
compared to H(2) (15)O/O (15)O PET in patients with chronic
cervical carotid artery occlusion. Neuroradiology 2008;50:745–51.
21. Iida H, Kanno I, Miura S, Murakami M, Takahashi K, Uemura K.
Error analysis of a quantitative cerebral blood flow measurement
using H2(15)O autoradiography and positron emission tomogra-
phy, with respect to the dispersion of the input function. J Cereb
Blood Flow Metab 1986;6:536–45.
22. Klotz E, König M. Perfusion measurements of the brain: using
dynamic CT for the quantitative assessment of cerebral ischemia in
acute stroke. Eur J Radiol 1999;30:170–84.
23. Anderson H, Price P. Clinical measurement of blood flow in
tumours using positron emission tomography: a review. Nucl
Med Commun 2002;23:131–8.
24. Takahashi N, Kikuchi H, Karasawa J. Dynamic CT in patients with
superficial temporal-middle cerebral artery anastomosis. AJNR
Am J Neuroradiol 1983;4:454–7.
25. Mineura K, Yasuda T, Kowada M, Shishido F, Ogawa T, Uemura K.
Positron emission tomographic evaluation of histological malignancy
in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose.
Neurol Res 1986;8:164–8.
26. Hu CH, Fang XM, Hu XY, Cui L. Analysis of the mismatched
manifestation between rCBF and rCBV maps in cerebral astrocy-
tomas. Clin Imaging 2009;33:417–23.
27. Lammertsma AA, Wise RJ, Cox TC, Thomas DG, Jones T. Mea-
surement of blood flow, oxygen utilisation, oxygen extraction
ratio, and fractional blood volume in human brain tumours and
surrounding oedematous tissue. Br J Radiol 1985;58:725–34.
28. Dandois V, Rommel D, Renard L, Jamart J, Cosnard G. Substitu-
tion of 11C-methionine PET by perfusion MRI during the follow-
up of treated high-grade gliomas: preliminary results in clinical
practice. J Neuroradiol 2010;37:89–97.
29. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR
contrast due to intravascular magnetic susceptibility perturbations.
Magn Reson Med 1995;34:555–66.
30. Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T,
Shigematsu Y, Liang L, Ge Y, Ushio Y, Takahashi M. Correlation
of MR imaging-determined cerebral blood volume maps with
histologic and angiographic determination of vascularity of glio-
mas. AJR Am J Roentgenol 1998;171:1479–86.
31. Sugahara T, Korogi Y, Kochi M, Ushio Y, Takahashi M. Perfusion-
sensitive MR imaging of gliomas: comparison between gradient-
1700 Eur J Nucl Med Mol Imaging (2012) 39:1691–1701
echo and spin-echo echo-planar imaging techniques. AJNR Am J
Neuroradiol 2001;22:1306–15.
32. Papadimitrou JM, Woods AE. Structural and functional char-
acteristics of the microcirculation in neoplasms. J Pathol
1975;116:65–72.
33. Donahue KM, Krouwer HG, Rand SD, Pathak AP, Marszalkowski
CS, Censky SC, Prost RW. Utility of simultaneously acquired
gradient-echo and spin-echo cerebral blood volume and morphology
maps in brain tumor patients. Magn Reson Med 2000;43:845–53.
34. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG,
Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz
M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden
DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-
VEGF receptor tyrosine kinase inhibitor, normalizes tumor vascu-
lature and alleviates edema in glioblastoma patients. Cancer Cell
2007;11:83–95.
35. Matthew E, Andreason P, Carson RE, Herscovitch P, Pettigrew K,
Cohen R, King C, Johanson CE, Paul SM. Reproducibility of
resting cerebral blood flow measurements with H2(15)O positron
emission tomography in humans. J Cereb Blood Flow Metab
1993;13:748–54.
36. Ito H, Kanno I, Ibaraki M, Suhara T, Miura S. Relationship
between baseline cerebral blood flow and vascular responses to
changes in PaCO2 measured by positron emission tomography in
humans: implication of inter-individual variations of cerebral vas-
cular tone. Acta Physiol (Oxf) 2008;193:325–30.
37. Rostrup E, Knudsen GM, Law I, Holm S, Larsson HB, Paulson
OB. The relationship between cerebral blood flow and volume in
humans. Neuroimage 2005;24:1–11.
38. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method
to measure hemodynamics in brain tumors: validation and appli-
cation of cerebral blood flow maps. AJNR Am J Neuroradiol
2000;21:462–70.
39. Packard SD, Mandeville JB, Ichikawa T, Ikeda K, Terada K, Niloff
S, Chiocca EA, Rosen BR, Marota JJ. Functional response of
tumor vasculature to PaCO2: determination of total and microvas-
cular blood volume by MRI. Neoplasia 2003;5:330–8.
40. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogene-
ity of the tumor vasculature. Semin Thromb Hemost 2010;36:321–31.
41. Blomqvist G, Lammertsma AA, Mazoyer B, Wienhard K. Effect
of tissue heterogeneity on quantification in positron emission to-
mography. Eur J Nucl Med 1995;22:652–63.
Eur J Nucl Med Mol Imaging (2012) 39:1691–1701 1701
